Announcement of License Agreement with Inabata & Co., Ltd. regarding the Manufacture and Sales of the Xeno-Modified Nucleic Acid Amidite “GuNA™” 2026/03/13 Notice Read
Our President & CEO, Mr. Hideaki Sato, will Speak at the 2nd Asian Drug Delivery & Formulation Summit 2025/11/11 Event Read
Our president & CEO, Mr. Hideaki Sato, will give a presentation at a seminar hosted by the Senri Life Science Foundation 2025/11/07 Event Read
Announcement of License Agreement with BioSpring GmbH for the Manufacture of Oligonucleotides Using XNA Technology 2025/10/09 Notice Read
